Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Surg Endosc. 2024 Nov;38(11):6908-6917. doi: 10.1007/s00464-024-11273-0. Epub 2024 Sep 25.
Metabolic and bariatric surgery (MBS) is gaining traction as a treatment option for adolescents with severe obesity. Since our weight center last published results in 2014, trends have shown increasingly diverse patient populations undergoing MBS and a shift from laparoscopic Roux-en-Y gastric bypass (LRYGB) to sleeve gastrectomy (LSG). We assessed outcomes including follow-up, weight loss, comorbidity resolution, and complications among our recent adolescent and young adult MBS patients.
This is a retrospective cohort analysis of patients under 21 years of age with severe obesity who underwent MBS at a single institution between 2014 and 2020. Data on demographics, comorbidities, body mass index (BMI), percent of total body weight loss (%TBWL) at various timepoints, and subsequent complications were collected via chart review. Regression examined associations between preoperative factors, follow-up, and %TBWL.
There were 79 patients of whom 73% were female; overall, 53% were White, 24% Hispanic, and 15% non-Hispanic Black. The majority (80%) of patients underwent LSG. Three-fourths of patients had follow-up data beyond 1 year, and half beyond 3 years. The median %TBWL of LSG patients was 23% at a median follow-up of 3.0 years, and LRYGB patients 28% at 2.4 years. No preoperative factors were associated with follow-up or final %TBWL, but 6-month %TBWL predicted final %TBWL. Preoperatively, 73% of patients had at least one weight-related comorbidity, and 57% had documented improvements in at least one after surgery. There were three 30-day readmissions and no mortalities.
This study, which is an update to a previous series from our center, reflects recent national trends with nearly half non-White patients and predominance of LSG over LRYGB. It adds to a growing body of evidence indicating that MBS is a safe and effective method of achieving weight loss and comorbidity resolution in adolescents with severe obesity.
代谢和减重手术(MBS)作为治疗严重肥胖青少年的一种选择正在逐渐受到关注。自我们的体重中心上次在 2014 年发布结果以来,趋势表明接受 MBS 的患者群体越来越多样化,并且从腹腔镜 Roux-en-Y 胃旁路术(LRYGB)转变为袖状胃切除术(LSG)。我们评估了最近在我们中心接受 MBS 的青少年和年轻成人患者的随访、减重、合并症解决和并发症等结果。
这是一项回顾性队列分析,研究对象为在一家机构于 2014 年至 2020 年期间接受 MBS 的年龄在 21 岁以下的严重肥胖患者。通过病历回顾收集人口统计学、合并症、体重指数(BMI)、各时间点的总体重减轻百分比(%TBWL)和随后的并发症数据。回归分析了术前因素、随访和%TBWL 之间的关联。
共有 79 名患者,其中 73%为女性;总体而言,53%为白人,24%为西班牙裔,15%为非西班牙裔黑人。大多数(80%)患者接受了 LSG。75%的患者有超过 1 年的随访数据,一半有超过 3 年的随访数据。LSG 患者的中位%TBWL 为 23%,中位随访时间为 3.0 年,LRYGB 患者为 28%,随访时间为 2.4 年。术前因素与随访或最终%TBWL 无关,但 6 个月时的%TBWL 可预测最终%TBWL。术前,73%的患者至少有一种与体重相关的合并症,57%的患者术后至少有一种合并症得到改善。有 3 例 30 天再入院,无死亡病例。
本研究是对我们中心之前系列研究的更新,反映了最近的全国趋势,近一半的患者是非白人,LSG 比 LRYGB 更为普遍。它增加了越来越多的证据,表明 MBS 是一种安全有效的方法,可以在严重肥胖的青少年中实现体重减轻和合并症的解决。